Background: Gut microbiota dysbiosis is a critical contributor to the pathogenesis and progression of inflammatory bowel disease (IBD). Darutigenol (DL), a natural compound has demonstrated significant anti-inflammatory activity, but its low oral bioavailability limits its application. However, t...

Fecal microbiota transplantation (FMT) has emerged as a promising therapeutic strategy for Inflammatory Bowel Disease (UC), though its clinical success appears contingent upon donor microbiota engraftment degree. While microbial colonization dynamics remain poorly understood, our study identifies...

Studies have revealed that gut microbiota dysbiosis and bile acid metabolism play pivotal roles in the pathogenesis of inflammatory bowel disease, and there exists a reciprocal interaction between gut microbiota and bile acid metabolism. S1PR2, a G protein-coupled receptor, has been demonstrated...

Background Probiotics have attracted considerable interest for ulcerative colitis (UC); however, their efficacy is highly strain-specific and the underlying molecular mechanisms remain incompletely understood.

Results Accumulating evidence indicates that bacterial extracellular vesicles (BE...